Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.

ABSTRACT:

Purpose

This phase I clinical trial is designed to assess the safety and feasibility of the epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR) T-cell generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer (NSCLC) patients. Compared to viral systems, the piggyBac transposon system is a simpler, more economical, and alternative way to introduce chimeric antigen receptor (CAR) transgenes into T cells.

Methods

This study recruited nine patients with advanced relapsed/refractory EGFR-positive NSCLC for two cycles of the piggyBac-generated EGFR-CAR T cells at dose of 1 × 10⁶ cells/kg or 3 × 10⁶ cells/kg of body weight. The patients were monitored for adverse events, clinical response, and pe

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC11801842 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature